Literature DB >> 32436948

Subacute Thyroiditis After Sars-COV-2 Infection.

Alessandro Brancatella1, Debora Ricci1, Nicola Viola1, Daniele Sgrò1, Ferruccio Santini1, Francesco Latrofa1.   

Abstract

CONTEXT: Subacute thyroiditis (SAT) is a thyroid disease of viral or postviral origin. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that began in Wuhan, China, has spread rapidly worldwide and Italy has been severely affected by this outbreak.
OBJECTIVES: The objective of this work is to report the first case of SAT related to SARS-CoV-2 infection.
METHODS: We describe the clinical, laboratory, and imaging features of an 18-year-old woman who came to our attention for fever, neck pain radiated to the jaw, and palpitations occurring 15 days after a SARS-CoV-2-positive oropharyngeal swab. Coronavirus disease 2019 (COVID-19) had been mild and the patient had completely recovered in a few days.
RESULTS: At physical examination the patient presented with a slightly increased heart rate and a painful and enlarged thyroid on palpation. At laboratory exams free thyroxine and free triiodothyronine were high, thyrotropin undetectable, and inflammatory markers and white blood cell count elevated. Bilateral and diffuse hypoechoic areas were detected at neck ultrasound. One month earlier, thyroid function and imaging both were normal. We diagnosed SAT and the patient started prednisone. Neck pain and fever recovered within 2 days and the remaining symptoms within 1 week. Thyroid function and inflammatory markers normalized in 40 days.
CONCLUSIONS: We report the first case of SAT after a SARS-CoV-2 infection. We alert clinicians to additional and unreported clinical manifestations associated with COVID-19. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; subacute thyroiditis; thyroid; virus

Mesh:

Substances:

Year:  2020        PMID: 32436948      PMCID: PMC7314004          DOI: 10.1210/clinem/dgaa276

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


Subacute thyroiditis (SAT) is a self-limited inflammatory thyroid disease characterized by neck pain, general symptoms, and thyroid dysfunction (1, 2). SAT is usually preceded by an upper respiratory tract infection. Direct and indirect evidence support a viral or postviral origin of this disease, and many viruses have been reported as potentially causative agents (3). Since January 2020, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in an emerging respiratory infection with a pandemical diffusion (4). Here, we report the first case of SAT in a patient affected by SARS-CoV-2.

Material and Methods

Case presentation

On February 28, 2020, an 18-year-old woman underwent an oropharyngeal swab for SARS-CoV-2 on the evidence that his father, who lived with her, had been hospitalized 2 days earlier because of COVID-19. Her swab turned out to be positive. In the next few days, the woman developed mild upper respiratory symptoms (rhinorrhea and cough). She was left untreated and recovered completely in 4 days (Fig. 1). Two additional swabs for SARS-CoV-2 (March 13 and 14) both turned out to be negative.
Figure 1.

Symptoms and maximum body temperatures referred to by the patient.

Symptoms and maximum body temperatures referred to by the patient. On March 17, the patient presented with sudden fever (37.5 °C), fatigue, palpitations, and anterior neck pain radiating to the jaw (Fig. 1). Because of worsening of the neck pain, on March 19 the patient was referred to us. For the previous finding of isolated hyperthyrotropinemia, on February 21 she had undergone thyroid evaluation: Thyroid function was normal, antibodies to thyroglobulin (TgAb) and to thyroperoxidase (TPOAb) negative, and thyroid ultrasound unremarkable (Table 1).
Table 1.

Clinical laboratory results

MeasureReference rangeFebruary 21March 19April 1April 27
 FT4, nmol/L11-2315.427.221.716.2
 FT3, pmol/L4.6-8.45.58.77.55.3
 TSH, mIU/L0.5-4.12.1< 0.040.22.9
 TgAb, IU/mL< 30< 30120.2
 TPOAb, IU/mL< 10< 10< 10
 TRAb, IU/mL< 1.5< 1.5
 Tg, µg/L5.6
White cell count, per L3800-11 00011 20069006600
 ESR, mm/h0-1390282
 CRP, mg/L< 26.91.20.9

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FT3, free triiodothyronine; FT4, free thyroxine; Tg, thyroglobulin; TgAb, thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; TRAb, TSH receptor antibodies; TSH, thyrotropin.

Clinical laboratory results Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FT3, free triiodothyronine; FT4, free thyroxine; Tg, thyroglobulin; TgAb, thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; TRAb, TSH receptor antibodies; TSH, thyrotropin.

Results

On March 19, at physical examination, the patient’s heart rate was 90 beats per minute and on palpation the thyroid gland was markedly painful and slightly tender and enlarged. The patient did not refer to any upper respiratory symptom. At laboratory exams, free thyroxine (FT4) and free triiodothyronine (FT3) were both mildly elevated, thyrotropin (TSH) undetectable, thyroglobulin (Tg) detectable at low level with positive TgAb. TPOAb and antibodies to the TSH receptor were negative. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and white cell blood count were high (Table 1). Thyroid ultrasound showed multiple, diffuse hypoechoic areas (Fig. 2). Thus, SAT was diagnosed and March 20 the patient started prednisone (25 mg/d). Neck pain and fever disappeared within 2 days and the remaining symptoms within 1 week (Fig. 1). On April 1, FT4 concentration had declined to the upper normal range, TSH had risen to almost normal level, ESR was slightly elevated, and white cell blood count and CRP were normal (Table 1). Steroid was progressively tapered and at the last evaluation (April 27), while taking prednisone 16 mg/day, the patient was asymptomatic. Thyroid functional tests and inflammatory markers were normal (Fig. 1 and Table 1).
Figure 2.

Thyroid ultrasound performed during the thyrotoxic phase, showing multiple hypoechoic areas (arrows).

Thyroid ultrasound performed during the thyrotoxic phase, showing multiple hypoechoic areas (arrows).

Discussion

SAT is a self-limited, inflammatory disorder characterized by neck pain and general symptoms, often associated with thyroid dysfunction (1, 2). Clinically, neck pain, frequently radiating to the upper neck, is the presenting symptom of SAT. On palpation, the thyroid is painful, tender, and enlarged. Systemic symptoms, including fever, fatigue, myalgia, and anorexia are common (1, 2). Thyroid dysfunction usually follows a triphasic course (thyrotoxicosis, hypothyroidism, and euthyroidism) that usually lasts 3 months. Symptomatic thyrotoxicosis occurs in the majority of patients, whereas clinical hypothyroidism is uncommon. Although the diagnosis of SAT is usually based on clinical grounds, laboratory tests and neck imaging are useful (1, 2, 5). A marked elevation of inflammatory markers (ESR and CRP) is common. In the acute phase, most individuals present with overt thyrotoxicosis (high FT4 levels and low to undetectable TSH levels) (1). As a consequence of the destructive process, the FT3/FT4 ratio is usually low and Tg elevated (1, 2). TSH receptor antibodies are generally absent, whereas TPOAb are positive in some and TgAb in a larger number of patients (6-8). During the acute phase, radionuclide thyroid scanning typically shows reduced or absent tracer uptake, whereas thyroid ultrasound shows bilateral hypoechoic areas associated with low to absent vascularization (5). Thyroid evaluation performed 1 month earlier in the patient herein reported had ruled out thyroid diseases. She then presented with clinical, biochemical, and imaging stigmata of SAT. Of note, as previously reported, SAT was associated with the de novo appearance of TgAb (6, 8). Because of positive TgAb, Tg levels were inappropriately normal (9). Although the benefit of glucocorticoid is debated (10), in our experience the administration of prednisone during the acute phase is associated with a faster resolution of symptoms and a lower risk of recurrence (11). Indeed, within 2 weeks of treatment, we obtained a complete recovery of symptoms and a remarkable improvement both in thyroid function and inflammatory markers. The etiology and the pathogenesis of SAT have not been completely understood, but it is common opinion that the disease is due to a viral infection or to a postviral inflammatory reaction in genetically predisposed individuals (1, 3). Some human leukocyte antigen (HLA) haplotypes (mainly HLA-Bw35, but also HLA-B67, HLA-B15/62, and HLA-Drw8) have been reported to predispose to SAT (12, 13). SAT is usually preceded by an upper respiratory infection and usually presents in association with characteristic symptoms of viral disease. In addition, several cases of the disease have been reported during viral outbreaks (2, 3). Some authors have reported a higher incidence of SAT in summer, during the outbreaks of echovirus and coxsackievirus (14, 15). Many other viruses, including mumps, adenovirus, orthomyxovirus, Epstein-Barr virus, hepatitis E, HIV, cytomegalovirus, dengue fever, and rubella have also been related to SAT (3, 16-18). At autopsy, thyroid injury was demonstrated in patients with SARS-CoV infection during the 2002 outbreak (19). However, coronavirus infection has never been associated with clinical SAT. In conclusion, to our knowledge, this is the first case of SAT related to SARS-CoV-2. Because of the chronological association, SARS-CoV-2 may be considered accountable for the onset of SAT. COVID-19, originating from Wuhan, is spreading around the world as a pandemic disease (4). Since initial detection of the virus, more than 3 million cases of COVID-19 have been confirmed worldwide and Italy has been severely affected since February 2020 (20). We therefore believe physicians should be alerted about the possibility of this additional clinical manifestation related to SARS-CoV-2 infection.
  19 in total

1.  A case of subacute thyroiditis associated with primary HIV infection.

Authors:  Benjamin Bouillet; Jean-Michel Petit; Lionel Piroth; Michel Duong; Jean-Baptiste Bourg
Journal:  Am J Med       Date:  2009-04       Impact factor: 4.965

2.  Acute hepatitis E virus infection and association with a subacute thyroiditis.

Authors:  Yamila Martínez-Artola; Daniel Poncino; María L García; María S Munné; Jorge González; Daniel S García
Journal:  Ann Hepatol       Date:  2015 Jan-Feb       Impact factor: 2.400

3.  High prevalence of subacute thyroiditis during summer season in Italy.

Authors:  E Martino; L Buratti; L Bartalena; S Mariotti; C Cupini; F Aghini-Lombardi; A Pinchera
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

4.  Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin.

Authors:  Francesco Latrofa; Debora Ricci; Sara Bottai; Federica Brozzi; Luca Chiovato; Paolo Piaggi; Michele Marinò; Paolo Vitti
Journal:  Thyroid       Date:  2018-03       Impact factor: 6.568

5.  Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis.

Authors:  Tadashi Arao; Yosuke Okada; Keiichi Torimoto; Akira Kurozumi; Manabu Narisawa; Sunao Yamamoto; Yoshiya Tanaka
Journal:  J UOEH       Date:  2015-06-01

6.  Thyroglobulin autoantibodies of patients with subacute thyroiditis are restricted to a major B cell epitope.

Authors:  F Latrofa; D Ricci; L Montanelli; M A Altea; A Pucci; A Pinchera; P Vitti
Journal:  J Endocrinol Invest       Date:  2012-09       Impact factor: 4.256

7.  Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing.

Authors:  N Ohsako; H Tamai; T Sudo; T Mukuta; H Tanaka; K Kuma; A Kimura; T Sasazuki
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

8.  Moderate Frequency of Anti-Thyroglobulin Antibodies in the Early Phase of Subacute Thyroiditis.

Authors:  Eijun Nishihara; Nobuyuki Amino; Takumi Kudo; Kazuyoshi Kohsaka; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Hirotoshi Nakamura; Akira Miyauchi
Journal:  Eur Thyroid J       Date:  2019-07-15

9.  Expanded dengue syndrome: subacute thyroiditis and intracerebral hemorrhage.

Authors:  Muhammad Zaman Khan Assir; Ali Jawa; Hafiz Ijaz Ahmed
Journal:  BMC Infect Dis       Date:  2012-10-03       Impact factor: 3.090

Review 10.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

View more
  106 in total

Review 1.  COVID-19-related thyroid conditions (Review).

Authors:  Florica Șandru; Mara Carsote; Răzvan Cosmin Petca; Ancuta Augustina Gheorghisan-Galateanu; Aida Petca; Ana Valea; Mihai Cristian Dumitrașcu
Journal:  Exp Ther Med       Date:  2021-05-13       Impact factor: 2.447

2.  A Case of Post-COVID-19 Subacute Thyroiditis.

Authors:  Maham A Mehmood; Monica Bapna; Mahnoor Arshad
Journal:  Cureus       Date:  2020-12-26

3.  The value of color Doppler ultrasound in the diagnosis of thyroid nodules: a systematic review and meta-analysis.

Authors:  Danbo Zhao; Yi Jing; Xiaoyi Lin; Bixia Zhang
Journal:  Gland Surg       Date:  2021-12

Review 4.  Post-acute COVID-19 syndrome.

Authors:  Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan
Journal:  Nat Med       Date:  2021-03-22       Impact factor: 53.440

Review 5.  Uncurtaining the effect of COVID-19 in diabetes mellitus: a complex clinical management approach.

Authors:  Shilpi Kashyap; Rajni Bala; Reecha Madaan; Tapan Behl
Journal:  Environ Sci Pollut Res Int       Date:  2021-05-21       Impact factor: 4.223

Review 6.  Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review.

Authors:  Eleni Korompoki; Maria Gavriatopoulou; Rachel S Hicklen; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Despina Fotiou; Kimon Stamatelopoulos; Evangelos Terpos; Anastasia Kotanidou; Carin A Hagberg; Meletios A Dimopoulos; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2021-05-14       Impact factor: 6.072

7.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

8.  Prognostic significance of low TSH concentration in patients with COVID-19 presenting with non-thyroidal illness syndrome.

Authors:  Jing-Bin Li; Fu-Er Lu; Jing Gong; Ding-Kun Wang; Hui Dong; Qing-Song Xia; Zhao-Yi Huang; Yan Zhao; Xing Chen; Fen Yuan
Journal:  BMC Endocr Disord       Date:  2021-05-27       Impact factor: 2.763

Review 9.  Cardio-Pulmonary Sequelae in Recovered COVID-19 Patients: Considerations for Primary Care.

Authors:  Zouina Sarfraz; Azza Sarfraz; Alanna Barrios; Radhika Garimella; Asimina Dominari; Manish Kc; Krunal Pandav; Juan C Pantoja; Varadha Retnakumar; Ivan Cherrez-Ojeda
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

Review 10.  Pathogenesis and Management of COVID-19.

Authors:  Khalid O Alfarouk; Sari T S AlHoufie; Samrein B M Ahmed; Mona Shabana; Ahmed Ahmed; Saad S Alqahtani; Ali S Alqahtani; Ali M Alqahtani; AbdelRahman M Ramadan; Mohamed E Ahmed; Heyam S Ali; Adil Bashir; Jesus Devesa; Rosa A Cardone; Muntaser E Ibrahim; Laurent Schwartz; Stephan J Reshkin
Journal:  J Xenobiot       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.